



FINAL

ENDOMETRIAL CANCER COMMITTEE  
THURSDAY, MAY 31, 2018, 9:00AM – 10:30AM  
MONROE ROOM, PALMER HOUSE HILTON HOTEL, CHICAGO  
CHAIR: S.GREGGI CO-CHAIR: C.CREUTZBERG  
HARMONIZATION LIAISONS: VERHOEVEN (OPS); TU/EMBLETON (STATS)  
*PLEASE SIGN ATTENDANCE FORMS*

### AGENDA

Welcome and Introductions  
COI Disclosures (real or perceived)  
Approval of report/minutes: November 2017 (posted on GCIG website)  
Motion: \_\_\_\_\_ Seconded: \_\_\_\_\_

Greggi

#### CLOSED/PUBLISHED STUDIES:

- JGOG 2047

Greggi

#### ONGOING TRIALS:

- ECCO
- PORTEC<sub>4</sub>
- BGOG-SIENDO/EN<sub>5</sub>
- NSGO : ENGOT-EN<sub>1</sub> / FANDANGO
- ENGOT-EN<sub>2</sub>-DGCG
- NSGO: ENGOT-EN<sub>3</sub> / PALEO
- NSGO: ENGOT-EN<sub>6</sub>
- MaNGO: AtTEnd

Greggi  
Creutzberg  
Vergote  
Mirza  
Creutzberg  
Mirza  
Mirza  
Fossati

#### UPDATE OF TRIALS IN DEVELOPMENT:

- AdvEnCa Retrospective Study;

Greggi

#### NEW PROPOSALS/CONCEPTS:

- SAVE Study

Gaffney

#### CHALLENGING DEBATE:

“Is it time to change?”

-introduction (S.Greggi) (3min)

-feasibility data from PORTEC<sub>4</sub> (C.Creutzberg) (15min)

-could biomolecular profiling on diagnostic biopsy help in tailoring surgery? (J.Sehouli) (15min)

-discussion (10min)

ADJOURN